| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S00108-006-1622-Y |
| P698 | PubMed publication ID | 16773364 |
| P2093 | author name string | J Braess | |
| W Hiddemann | |||
| K Spiekermann | |||
| T Büchner | |||
| C Buske | |||
| M Feuring-Buske | |||
| P2860 | cites work | CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations | Q27824809 |
| ??? | Q28202843 | ||
| Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype | Q27824844 | ||
| Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse | Q28204295 | ||
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 | ||
| Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients | Q31892904 | ||
| Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). | Q33343994 | ||
| Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 | ||
| Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. | Q34056639 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. | Q34155766 | ||
| Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management | Q34435497 | ||
| The theory of APL. | Q34435538 | ||
| The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial | Q34517235 | ||
| Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease | Q34524219 | ||
| Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias | Q34818452 | ||
| Disruption of differentiation in human cancer: AML shows the way. | Q35058575 | ||
| Targeted therapies in myeloid leukemia | Q35646312 | ||
| Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia | Q40572385 | ||
| Oncogenic transcription factors in the human acute leukemias | Q41628889 | ||
| Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial | Q43615357 | ||
| Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial | Q43622754 | ||
| Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study | Q43806484 | ||
| All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial | Q43963835 | ||
| Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. | Q45038438 | ||
| Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia | Q45073090 | ||
| World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. | Q46038765 | ||
| Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute mye | Q73159091 | ||
| Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML | Q73769144 | ||
| Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group | Q74171252 | ||
| Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome | Q77293823 | ||
| Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group | Q77850380 | ||
| Cytogenetic findings in adult de novo acute myeloid leukaemia. A population‐based study of 303/337 patients | Q79129535 | ||
| Acute myeloid leukemia | Q81052131 | ||
| P921 | main subject | acute myeloid leukemia | Q264118 |
| P304 | page(s) | S33-9 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | Die Innere Medizin | Q1194574 |
| P1476 | title | [Risk-adapted therapy of acute myeloid leukemia] | |
| P478 | volume | 47 Suppl 1 |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.